|
[1] TANAKA A,LEUNG PSC,GERSHWIN ME. Evolution of our understanding of PBC[J]. Best Pract Res Clin Gastroenterol,2018,34-35:3-9.
|
|
[2] GULAMHUSEIN AF,HIRSCHFIELD GM. Pathophysiology of primary biliary cholangitis[J]. Best Pract Res Clin Gastroenterol,2018,34-35:17-25.
|
|
[3] BANALES JM,SÁEZ E,URIZ M,et al. Up-regulation of microRNA 506 leads to decreased Cl-/HCO3-anion exchanger2 expression in biliary epithelium of patients with primary biliary cirrhosis[J]. Hepatology,2012,56(2):687-697.
|
|
[4] MA WT,CHEN DK. Immunological abnormalities in patients with primary biliary cholangitis[J]. Clin Sci(Lond),2019,133(6):741-760.
|
|
[5] WEBB GJ,SIMINOVITCH KA,HIRSCHFIELD GM. The immunogenetics of primary biliary cirrhosis:A comprehensive review[J]. J Autoimmun,2015,64:42-52.
|
|
[6] GULAMHUSEIN AF,JURAN BD,LAZARIDIS KN. Genomewide association studies in primary biliary cirrhosis[J]. Semin Liver Dis,2015,35(4):392-401.
|
|
[7] YOSHIDA K,YANG GX,ZHANG W,et al. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice[J]. Hepatology,2009,50(5):1494-1500.
|
|
[8] LAN RY,SALUNGA TL,TSUNEYAMA K,et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis[J]. J Autoimmun,2009,32(1):43-51.
|
|
[9] YANG W,YAO Y,YANG YQ,et al. Differential modulation by IL-17A of cholangitis versus colitis in IL-2Rαdeleted mice[J]. PLo S One,2014,9(8):e105351.
|
|
[10] KAWATA K,TSUDA M,YANG GX,et al. Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis[J]. PLo S One,2013,8(9):e74225.
|
|
[11] SHI T,ZHANG T,ZHANG L,et al. The distribution and the fibrotic role of elevated inflammatory Th17 cells in patients with primary biliary cirrhosis[J]. Medicine(Baltimore),2015,94(44):e1888.
|
|
[12] ZHANG H,BERNUZZI F,LIEO A,et al. Therapeutic potential of IL-17-mediated signaling pathway in autoimmune liver diseases[J]. Mediators Inflamm,2015,2015:436450.
|
|
[13] YANG CY,MA X,TSUNEYAMA K,et al. IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis:Implications for therapy[J]. Hepatology,2014,59(5):1944-1953.
|
|
[14] ELYAMAN W,BRADSHAW EM,UYTTENHOVE C,et al. IL-9induces differentiation of Th17 cells and enhances function of Fox P3+natural regulatory T cells[J]. Proc Natl Acad Sci U S A,2009,106(31):12885-12890.
|
|
[15] XIAO X,BIAN ZL,MIAO Q,et al. Expression and clinical significance of interleukin-9 in patients with primary biliary cirrhosis[J]. Chin J Gastroenter,2014,19(8):464-467.(in Chinese)肖潇，卞兆连，苗琪，等．白细胞介素-9在原发性胆汁性肝硬化患者中的表达及其临床意义[J]．胃肠病学，2014,19(8):464-467.
|
|
[16] LI H,CHEN Y,ZHANG L,et al. Expression of Th9 cells from peripheral blood of primary biliary cirrhosis patients and its clinical significance[J]. J Mod Lab Med,2016,31(3):16-18,21.(in Chinese)李虎，陈燕，张蕾，等．原发性胆汁性肝硬化患者外周血Th9细胞表达增高及其临床意义[J]．现代检验医学杂志，2016,31(3):16-18,21.
|
|
[17] WANG Q,LUO DM,SUN XF,et al. Increased expression of IL-9 in peripheral blood and liver tissues of patients with primary biliary cirrhosis[J]. Chin J Cell Mol Immunol,2016,32(12):1679-1682.(in Chinese)王倩，罗德梅，孙晓凤，等．原发性胆汁性肝硬化患者血清和肝组织白细胞介素9表达增强[J]．细胞与分子免疫学杂志，2016,32(12):1679-1682.
|
|
[18] QIN SY,LU DH,GUO XY,et al. A deleterious role for Th9/IL-9in hepatic fibrogenesis[J]. Sci Rep,2016,6:18694.
|
|
[19] GUO X,CEN Y,WANG J,et al. CXCL10-induced IL-9promotes liver fibrosis via Raf/MEK/ERK signaling pathway[J]. Biomed Pharmacother,2018,105:282-289.
|
|
[20] ISSE K,HARADA K,NAKANUMA Y. IL-8 expression by biliary epithelial cells is associated with neutrophilic infiltration and reactive bile ductules[J]. Liver Int,2007,27(5):672-680.
|
|
[21] YOKOYAMA T,KOMORI A,NAKAMURA M,et al. Human intrahepatic biliary epithelial cells function in innate immunity by producing IL-6 and IL-8 via the TLR4-NF-kappaB and-MAPK signaling pathways[J]. Liver Int,2006,26(4):467-476.
|
|
[22] REN Y,POON RT,TSUI HT,et al. Interleukin-8 serum levels in patients with hepatocellular carcinoma:Correlations with clinicopathological features and prognosis[J]. Clin Cancer Res,2003,9(1):5996-6001.
|
|
[23] HARADA K,HIROHARA J,UENO Y,et al. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis:National data from Japan[J]. Hepatology,2013,57(5):1942-1949.
|
|
[24] ZIMMERMANN HW,SEIDLER S,GASSLER N,et al. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis[J]. PLo S One,2011,6(6):e21381.
|
|
[25] YANG M,HUANG FL,FU HT,et al. Expressions and clinical significances of IL-8 and its receptors(CXCR1/2)in peripheral blood from the patients with primary biliary cirrhosis[J]. Chin J Clin Lab Sci,2014,32(5):362-365.(in Chinese)杨敏，黄凤楼，傅海涛，等．原发性胆汁性肝硬化患者外周血IL-8及其受体CXCR1、CXCR2的表达及临床意义[J]．临床检验杂志，2014,32(5):362-365.
|
|
[26] AKBEROVA D,KIASSOV AP,ABDULGANIEVA D. Serum cytokine levels and their relation to clinical features in patients with autoimmune liver diseases[J]. J Immunol Res,2017,2017:9829436.
|
|
[27] UMEMURA T,SEKIGUCHI T,JOSHITA S,et al. Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis[J]. Liver Int,2017,37(6):897-905.
|
|
[28] NEUMAN M,ANGULO P,MALKIEWICZ I,et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis[J]. J Gastroenterol Hepatol,2002,17(2):196-202.
|
|
[29] ZHANG W,TSUDA M,YANG GX,et al. Deletion of interleukin-6in mice with the dominant negative form of transforming growth factor beta receptor II improves colitis but exacerbates autoimmune cholangitis[J]. Hepatology,2010,52(1):215-222.
|
|
[30] SPADARO A,SCRIVO R,RICCIERI V,et al. Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis[J]. Joint Bone Spine,2008,75(1):87-89.
|
|
[31] TRIANTAFILLIDIS JK,DURAKIS S,MERIKAS E. Crohn’s disease of the small bowel,complicated by primary biliary cirrhosis,Hashimoto thyroiditis,and Raynaud’s phenomenon:Favorable response of all disorders to adalimumab treatment[J].Gastroenterol Hepatol Bed Bench,2013,6(2):101-105.
|
|
[32] DEL ROSS T,RUFFATTI A,FLOREANI A,et al. The efficacy of adalimumab in psoriatic arthritis concomitant to overlapping primary biliary cholangitis and primary sclerosing cholangitis:A case report[J]. BMC Musculoskelet Disord,2016,17(1):485.
|
|
[33] CHEN LP,CAI M,ZHANG QH,et al. Activation of interleukin-6/STAT3 in rat cholangiocyte proliferation induced by lipopolysaccharide[J]. Dig Dis Sci,2009,54(3):547-554.
|
|
[34] SAITO E,SATO S,NOGI S,et al. A case of rheumatoid arthritis and limited systemic sclerosis overlap successfully treated with tocilizumab for arthritis and concomitant generalized lymphadenopathy and primary biliary cirrhosis[J]. Case Rep Rheumatol,2014,2014:386328.
|
|
[35] CHEN J,HOU X,JIA H,et al. Regulatory T cells with a defect in inhibition on co-stimulation deteriorated primary biliary cholangitis[J]. Oncotarget,2017,8(65):108406-108417.
|
|
[36] LIASKOU E,PATEL SR,WEBB G,et al. Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-gamma secreting cells[J]. J Autoimmun,2018,94:143-155.
|
|
[37] ZHANG W,SHARMA R,JU ST,et al. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis[J]. Hepatology,2009,49(2):545-552.
|
|
[38] TANAKA H,ZHANG W,YANG GX,et al. Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+)regulatory T cells[J]. Clin Exp Immunol,2014,178(2):253-261.
|
|
[39] WANG L,HAN Y. An excerpt of primary biliary cholangitis:2018practice guidance from the American Association for the Study of Liver Diseases[J]. J Clin Hepatol,2018,34(11):2300-2304.(in Chinese)王璐，韩英．《2018年美国肝病学会原发性胆汁性胆管炎实践指导》摘译[J]．临床肝胆病杂志，2018,34(11):2300-2304.
|
|
[40] HIRSCHFIELD GM,GERSHWIN ME,STRAUSS R,et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid:A proof-of-concept study[J]. Hepatology,2016,64(1):189-199.
|
|
[41] TODO S,YAMASHITA K,GOTO R,et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation[J]. Hepatology,2016,64(2):632-643.
|
|
[42] POPP F,SEMELA D,von KEMPIS J,et al. Improvement of primary biliary cholangitis(PBC)under treatment with sulfasalazine and abatacept[J]. BMJ Case Rep,2018,2018:bcr-2018-224205.
|
|
[43] BOWLUS CL,YANG GX,LIU CH,et al. Therapeutic trials of biologics in primary biliary cholangitis:An open label study of abatacept and review of the literature[J]. J Autoimmun,2019,101:26-34.
|
|
[44] KISHIDA K,KOHYAMA M,KURASHIMA Y,et al. Negative regulation of DSS-induced experimental colitis by PILRalpha[J]. Int Immunol,2015,27(6):307-314.
|
DownLoad: